JCXH-105 / Immorna - LARVOL DELTA

JCXH-105-021: A Phase 2 Study to Evaluate JCXH-105, an srRNA-based Herpes Zoster Vaccine (clinicaltrials.gov) - P2 | N=467 | Active, not recruiting | Sponsor: Immorna Biotherapeutics, Inc. | Recruiting ➔ Active, not recruiting

Enrollment closed • Herpes Zoster • Infectious Disease • Varicella Zoster

JCXH-105-021: A Phase 2 Study to Evaluate JCXH-105, an srRNA-based Herpes Zoster Vaccine (clinicaltrials.gov) - P2 | N=460 | Recruiting | Sponsor: Immorna Biotherapeutics, Inc. | Not yet recruiting ➔ Recruiting

Enrollment open • Herpes Zoster • Infectious Disease • Varicella Zoster • CD4 • CD8 • IFNG • IL2 • TNFA

A First-in-Human Study to Evaluate JCXH-105, an SrRNA-based Herpes Zoster Vaccine (clinicaltrials.gov) - P1 | N=75 | Completed | Sponsor: Immorna Biotherapeutics, Inc. | Active, not recruiting ➔ Completed

Trial completion • Herpes Zoster • Infectious Disease • Varicella Zoster

A Phase 2 Study to Evaluate JCXH-105, an SrRNA-based Herpes Zoster Vaccine (clinicaltrials.gov) - P2 | N=460 | Not yet recruiting | Sponsor: Immorna Biotherapeutics, Inc.

New P2 trial • Herpes Zoster • Infectious Disease • Varicella Zoster • CD4 • CD8 • IFNG • IL2 • TNFA

A First-in-Human Study to Evaluate JCXH-105, an srRNA-based Herpes Zoster Vaccine (clinicaltrials.gov) - P1 | N=75 | Active, not recruiting | Sponsor: Immorna Biotherapeutics, Inc. | Recruiting ➔ Active, not recruiting

Enrollment closed • Herpes Zoster • Infectious Disease • Varicella Zoster

A First-in-Human Study to Evaluate JCXH-105, an srRNA-based Herpes Zoster Vaccine (clinicaltrials.gov) - P1 | N=75 | Recruiting | Sponsor: Immorna Biotherapeutics, Inc.

New P1 trial • Herpes Zoster • Infectious Disease • Varicella Zoster • CD4